心瑋醫療傳上限171元定價
內地神經介入醫療器械公司心瑋醫療科技 (06609) 將在8月20日上市。據外媒報道指,心瑋醫療計劃以招股價區間上限171元定價,若以此計算,公司集資金額達11.3億元。據券商數據顯示,心瑋醫療合共錄得216.7億元的孖展認購,以公開發售集資近1.13億元計算,超額認購近191倍。
公司計劃發售660萬股,一成作香港公開發售,招股價介乎160元至171元,每手50股,一手入場費約8636元。
心瑋醫療主要從事神經介入醫療器械研發、生產及商業化。截至去年9月底止首9個月,公司虧損達6774.5萬元人民幣,2019年同期虧損達6248萬元人民幣。公司於去年首次錄得收入達729萬元人民幣。
所得款項約45.3%預期將分配至核心產品;約39.9%分配至管線內的其他在研產品;約4.8%用於爲透過內部研究提升研發能力及持續擴充產品組合提供資金;10%作營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.